Opendata, web and dolomites

NOVOBIOME-1 SIGNED

Development of a novel human derived probiotic species platform - Phase 1

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOVOBIOME-1 project word cloud

Explore the words cloud of the NOVOBIOME-1 project. It provides you a very rough idea of what is the project "NOVOBIOME-1" about.

models    healthy    innovative    generation    fee    clients    live    ngps    73    lbps    first    dosages    worldwide    cultivation    fast    dutch    sold    annum    functional    winclove    2018    positive    instrument    35    track    million    probiotics    countries    struggling    probiotic    leader    play    radically    provides    limited    segment    untapped    intrinsic    platform    formulations    human    technological    microbiota    whereas    tackle    global    successful    market    full    service    attractive    coming    commercialization    25    business    maximize    novobiome    8m    techniques    sme    b2b    infrastructure    ngp    substantially    sustainable    combines    house    customers    14    companies    fte    biotherapeutic    anticipates    daily    cycle    company    anticipated    manufacturing    moving    flourishing    timeline    leverages    turnover    services    commercializing    reached    mainly    130    facilities    grow    origins    generate    successfully   

Project "NOVOBIOME-1" data sheet

The following table provides information about the project.

Coordinator
WINCLOVE BV 

Organization address
address: HULSTWEG 11
city: AMSTERDAM
postcode: 1032 LB
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WINCLOVE BV NL (AMSTERDAM) coordinator 50˙000.00

Map

 Project objective

The global probiotics market is flourishing and anticipated to grow substantially in the coming years due the highly promising application of next-generation probiotics (NGPs) as live biotherapeutic products (LBPs). Whereas traditional probiotics are mainly derived from non-human origins with limited positive effects, NGPs are human-derived and play a key role in a healthy microbiota. All major probiotic companies are now moving into this field, however they are struggling with product development due to the intrinsic properties of NGPs. As a result, no NGP products have successfully reached the market yet. NGP product development requires radically new techniques for cultivation and production. This untapped market segment is highly attractive for Winclove. To tackle this problem, Winclove is developing the NOVOBIOME platform – covering the full cycle of NGP product development. Winclove’s approach leverages its already functional in-house facilities and infrastructure and combines it with innovative models and technological methods that can fast-track the timeline of NGP product to market for our clients. Winclove, an innovative Dutch SME, is a leader in microbiota-management, which has been offering services in research, development and manufacturing of probiotic formulations for over 25 years. Winclove has been very successful in growing the company into a sustainable business with 73 FTE, growing 14% per annum on average. It provides its services to over 80 customers in 35 countries worldwide. As such, it has sold via its clients over 130 million daily dosages in 2018. Winclove aims to provide the NOVOBIOME platform as a B2B fee for service to dedicated innovative companies that are working on NGP-based LBPs. Winclove anticipates to generate €8M in turnover within the first 5 years of commercializing the NOVOBIOME platform. This SME-1 instrument project NOVOBIOME phase 1 enables Winclove to investigate the requirements to maximize the European commercialization

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVOBIOME-1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVOBIOME-1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

BOND (2018)

Parental BONDing for a better start in life

Read More  

UAVEndure II (2019)

Innovative fuel cell propulsion technology enabling long endurance for small UAVs

Read More  

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More